Discontinuing Omalizumab Treatment in Super-Responder Patients with Allergic Severe Asthma: Can the Baseline Total IgE Level Be Used as a Biological Marker to Decide Discontinuing Omalizumab Treatment?

MLA

Arslan, Bahar, et al. “Discontinuing Omalizumab Treatment in Super-Responder Patients with Allergic Severe Asthma: Can the Baseline Total IgE Level Be Used as a Biological Marker to Decide Discontinuing Omalizumab Treatment?” International Archives of Allergy and Immunology, vol. 183, no. 10, 2022, pp. 1071–77. EBSCOhost, https://doi.org/10.1159/000525723.

APA

Arslan, B., Paçacı Çetin, G., Türk, M., Gülmez, İ., & Yılmaz, İ. (2022). Discontinuing Omalizumab Treatment in Super-Responder Patients with Allergic Severe Asthma: Can the Baseline Total IgE Level Be Used as a Biological Marker to Decide Discontinuing Omalizumab Treatment? International Archives of Allergy and Immunology, 183(10), 1071–1077. https://doi.org/10.1159/000525723

Chicago

Arslan, Bahar, Gülden Paçacı Çetin, Murat Türk, İnci Gülmez, and İnsu Yılmaz. 2022. “Discontinuing Omalizumab Treatment in Super-Responder Patients with Allergic Severe Asthma: Can the Baseline Total IgE Level Be Used as a Biological Marker to Decide Discontinuing Omalizumab Treatment?” International Archives of Allergy and Immunology 183 (10): 1071–77. doi:10.1159/000525723.